0.4437
1.98%
+0.0086
After Hours:
.4589
0.0152
+3.43%
ASLAN Pharmaceuticals Ltd ADR stock is currently priced at $0.4437, with a 24-hour trading volume of 177.33K.
It has seen a +1.98% increased in the last 24 hours and a -9.63% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.4281 pivot point. If it approaches the $0.4535 resistance level, significant changes may occur.
Previous Close:
$0.4351
Open:
$0.4309
24h Volume:
177.33K
Market Cap:
$10.04M
Revenue:
-
Net Income/Loss:
$-45.19M
P/E Ratio:
-0.1425
EPS:
-3.1147
Net Cash Flow:
-
1W Performance:
+7.96%
1M Performance:
-9.63%
6M Performance:
-56.92%
1Y Performance:
-89.98%
ASLAN Pharmaceuticals Ltd ADR Stock (ASLN) Company Profile
Name
ASLAN Pharmaceuticals Ltd ADR
Sector
Industry
Phone
65 6222 4235
Address
No. 12-03 UE Square, 83 Clemenceau Avenue, Singapore
ASLAN Pharmaceuticals Ltd ADR Stock (ASLN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-09-21 | Initiated | Jefferies | Buy |
Jan-14-19 | Reiterated | H.C. Wainwright | Buy |
ASLAN Pharmaceuticals Ltd ADR Stock (ASLN) Latest News
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.12% - MSN
MSN
ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Sees Large Growth in Short Interest - Defense World
Defense World
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.62% - MSN
MSN
ASLAN Pharmaceuticals Excels in Eblasakimab Trials - TipRanks.com - TipRanks
TipRanks
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab ... - Investing.com India
Investing.com India
Eblasakimab Shows Promise for AD Patients - TipRanks.com - TipRanks
TipRanks
ASLAN Pharmaceuticals Ltd ADR Stock (ASLN) Financials Data
ASLAN Pharmaceuticals Ltd ADR (ASLN) Net Income 2024
ASLN net income (TTM) was -$45.19 million for the quarter ending September 30, 2023, a +1.27% increase year-over-year.
ASLAN Pharmaceuticals Ltd ADR (ASLN) Earnings per Share 2024
ASLN earnings per share (TTM) was -$2.8647 for the quarter ending September 30, 2023, a +18.15% growth year-over-year.
About ASLAN Pharmaceuticals Ltd ADR
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in developing therapeutics for global markets. It targets diseases that are highly prevalent in Asia, and orphan indications in the United States and Europe. The company's product pipeline includes Varlitinib, a reversible small molecule pan-human epidermal growth factor receptor inhibitor that is being studied in global pivotal trials (TreeTopp) for biliary tract cancer, and conducting Phase 2/3 clinical trials for gastric cancer, as well as testing in a single-arm pivotal clinical trial in biliary tract cancer in China. It has exclusive global rights to develop, manufacture, and commercialize varlitnib for all human and animal therapeutic, diagnostic, and prophylactic uses. It is also developing ASLAN003, an orally active potent inhibitor of human dihydroorotate dehydrogenase that is in Phase 2 clinical trails to treat acute myeloid leukemia; and ASLAN004, an interleukin 4/interleukin 13 receptor antibody for the treatment of severe atopic dermatitis and asthma. The company has partnerships with Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL. ASLAN Pharmaceuticals Limited was founded in 2010 and is headquartered in Singapore.
Cap:
|
Volume (24h):